Kevin Mudd

MabVax Therapeutics at Mabvax Therapeutics Inc

Kevin Mudd's Professional Contact Details

Email (Verified)

****@mabvax.com

Get Email Address

(908) 938-1475

Location

San Diego, California, US

Company

Mabvax Therapeutics Inc

Person Seniority

entry

Kevin Mudd's Current Company Details

Mabvax Therapeutics Inc

San Diego, California, US • 20 Employees

biotechnology

MabVax Therapeutics (Nasdaq: MBVX) is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer. Our antibody MVT-5873, is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9, and is currently in Phase 1 clinical trials as a therapeutic agent for patients with pancreatic cancer and other CA19-9 positive tumors. With our collaborators including Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon Research Institute, Honor Health and Imaging Endpoints, we have treated 50 patients with either our therapeutic antibody designated as MVT-5873 or our PET imaging diagnostic product designated as MVT-2163 in Phase 1 clinical studies, and demonstrated early safety, specificity for the target and a potential efficacy signal. Patient dosing has commenced for our lead development program in Phase 1 clinical study of the Company's radioimmunotherapy product MVT-1075.

Public Symbol

MBVX

Founded Year

2006

Organization Website

mabvax.com

Organization Languages

English

Current Technologies

outlook

apache

google analytics